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T lymphocytes recognize peptides presented in the
context of major histocompatibility complex (MHC) mol-
ecules on the surface of antigen presenting cells. Recog-
nition specificity is determined by the  T cell receptor
(TCR). The T lymphocyte surface glycoproteins CD8 and
CD4 enhance T cell antigen recognition by binding to
MHC class I and class II molecules, respectively. Bio-
physical measurements have determined that equilib-
rium binding of the TCR with natural agonist peptide-
MHC (pMHC) complexes occurs with KD values of 1–50
M. The pMHCI/CD8 and pMHCII/CD4 interactions are
significantly weaker than this (KD >100 M), and the
relative roles of TCR/pMHC and pMHC/coreceptor affin-
ity in T cell activation remain controversial. Here, we
engineer mutations in the MHCI heavy chain and 2-
microglobulin that further reduce or abolish the
pMHCI/CD8 interaction to probe the significance of
pMHC/coreceptor affinity in T cell activation. We dem-
onstrate that the pMHCI/CD8 coreceptor interaction re-
tains the vast majority of its biological activity at affin-
ities that are reduced by over 15-fold (KD > 2 mM). In
contrast to previous reports, we observe that the weak
interaction between HLA A68 and CD8, which falls
within this spectrum of reduced affinities, retains sub-
stantial functional activity. These findings are dis-
cussed in the context of current concepts of coreceptor
dependence and the mechanism by which TCR corecep-
tors facilitate T cell activation.
T lymphocytes recognize protein antigens in the form of short
peptides presented in association with major histocompatibility
complex (MHC)1 molecules on the surface of target cells. Anti-
gen specificity is conferred by the T cell receptor (TCR), whose
highly variable complementarity determining regions interact
with the peptide-binding platform of the MHC molecule (1, 2).
The peptide-MHC complex (pMHC) also interacts with the T
cell surface glycoproteins CD8 and CD4, which bind to invari-
able regions of the MHC class I and II molecules, respectively
(3–7). The binding sites for CD8 and CD4 are separate from the
TCR-recognized (2), peptide-binding domains of MHC mole-
cules, and allow a single MHC molecule to be bound simulta-
neously by both TCR and either CD8 or CD4 (5, 6). The cyto-
plasmic domains of CD8 and CD4 are known to interact with
the T cell-specific intracellular protein-tyrosine kinase p56lck
(8, 9). This kinase is critical for the initiation of the TCR-
mediated signal transduction cascade (10). The recruitment of
essential signaling components to the cytoplasmic side of the
TCR by simultaneous binding of either CD8 or CD4 to the same
pMHC enhances TCR-mediated signal transduction (11–13).
Thus, CD8 and CD4 act as coreceptors for antigen in concert
with the antigen-specific TCR during the process of T cell
recognition and activation.
Whereas CD8 and CD4 appear to have similar biological
roles, they have little structural similarity (14, 15). CD8 is
present on the lymphocyte cell surface as either a disulfide-
bonded  homodimeric or  heterodimeric molecule. CD8
predominates on cells expressing pMHCI-specific  TCRs
(16). The CD8 chain recruits signaling components to the
cytoplasmic side of the TCR/pMHC interaction (17, 18) and
provides the majority of the binding energy in the CD8
heterodimer (19). The globular head domains of murine CD8
and CD8 bind to pMHCI with similar affinity (20). Cell-cell
adhesion assays have shown that human CD8 and CD8
mediate adherence to pMHCI equally (21). Despite similar
affinities for pMHCI,  heterodimer is more efficient than 
homodimer in promoting the response to antigen (22). This
suggests a distinct function for CD8. Recent evidence throws
light on this role. First, it has been shown that CD8 is palmi-
toylated at a membrane-proximal cysteine (23). This palmitoy-
lation mediates the partitioning of CD8 in ordered, cholesterol-
and sphingolipid-enriched, membrane microdomains known as
lipid rafts or detergent-insoluble membranes (23). The short
CD8 cytoplasmic domain also enables constitutive association
with the TCR/CD3 complex and recruits this antigen recogni-
tion complex to lipid rafts (24). Rafts exclude inhibitory phos-
phatases, such as CD45, and have been shown to be privileged
sites for the induction of the TCR-associated signal transduc-
tion cascade (25–29). CD8-mediated recruitment of the TCR
to lipid rafts might therefore explain the greater efficiency of
CD8 in promoting the response to antigen. Second, it has
been shown that the pMHCI/CD8 interaction is not fixed but
can be developmentally regulated by glycosylation (30). Gly-
cans on the CD8 stalk appear to modulate the ability of the
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distal binding surface of the dimeric CD8 globular head do-
mains to bind pMHCI (31). This differential glycosylation, lead-
ing to altered pMHCI binding, highlights a further potential
role of CD8. In contrast to CD8, CD4 is a single polypeptide.
The cytoplasmic domain of CD4, like that of CD8, is known to
interact with p56lck (9). Further work is required to determine
whether the single polypeptide of CD4 also incorporates the
roles recently ascribed to the CD8 chain.
The TCR and CD8 or CD4 coreceptors bind peptide-MHC
independently and with distinct kinetics (32, 33). The affinity
of pMHC/coreceptor interactions are at the low extreme of
those described for cell-cell interaction molecules (7, 32). Equi-
librium binding of human CD8 has been measured with
several different HLA A, B, and C gene products and occurs at
KD values of greater than 100 M (34). The pMHCII/CD4 in-
teraction is similarly weak (KD  200 M) (33). Here we exam-
ine the role of CD8 in antigen recognition using mutational
changes in the 3 domain of MHCI and the 2-microglobulin
subunit. These studies have enabled us to assess the contribu-
tion of the binding energy provided by the extracellular
pMHCI/CD8 interaction to the activation of human anti-viral
cytotoxic T lymphocytes (CTL).
EXPERIMENTAL PROCEDURES
Inclusion Body Preparation—Biotin-tagged HLA-A2 and HLA-A682
heavy chains were expressed under the control of a T7 promoter as
insoluble inclusion bodies in Escherichia coli strain BL21(DE3)pLysS
(Novagen). Isopropyl-1-thio--D-galactopyranoside-induced E. coli were
lysed by repeated freeze/thaw cycles to release inclusion bodies that
were subsequently purified by washing with a 0.5% Triton X-100 buffer
(Sigma) as described previously (35). The D227K/T228A mutation in
the 3 domain of HLA A2 has been shown to abrogate CD8 binding (12);
the corresponding A245V mutation reduces CD8 binding 5-fold (34).
D227K/T228A and residue 245 mutants of HLA A2 and HLA A68 heavy
chains, together with 2-microglobulin (2m) and K58E2m (36), were
produced using the same expression system.
Production of Soluble Peptide-MHC Class I—Soluble biotinylated
MHC class I monomers were produced as described previously (36).
Briefly, either HLA A2 or HLA A68 heavy chain and 2m inclusion body
preparations were denatured separately in 8 M urea buffer (Sigma) and
mixed at a 1:1 molar ratio. pMHCI was refolded in 2-mercaptoethyl-
amine/cystamine (Sigma) redox buffer with added synthetic peptide
(Reseach Genetics Invitrogen Corp., Huntsville, AL). HLA A2 heavy
chains were refolded with the HIV p17 Gag epitope SLYNTVATL (res-
idues 77–85) or the influenza matrix protein GILGFVFTL (residues
58–66). HLA A68 heavy chain was refolded with the HIV-1 Tat epitope
ITKGLGISYGR (37). Following buffer exchange into 10 mM Tris, pH
8.1, refolded monomer was purified by anion exchange. Purified mono-
mers were biotinylated as previously described (35) using d-biotin (Sig-
ma) and BirA enzyme. Excess biotin was removed by gel filtration.
Surface Plasmon Resonance—SPR analysis of biomolecular interac-
tions between the MHC class I monomers and human soluble CD8
(sCD8) was performed on a BIAcore 3000TM (BIAcore AB, St. Albans,
UK). sCD8 was prepared as described previously (36, 38). For anal-
ysis, all proteins were diluted into HBS-EP buffer (BIAcore AB) con-
taining 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and
0.005% Surfactant P20. Standard amine coupling kit (BIAcore AB) was
used to activate the surface of a research grade CM5 sensor chip
(BIAcore AB). Streptavidin was covalently coupled to the chip surface
via primary amines by injecting a 0.2 mg/ml streptavidin solution
(Sigma) diluted in 10 mM sodium acetate, pH 4.5, over the surface.
Biotinylated monomers were immobilized onto the chip surface at
1000 response units (RU) in each flow cell. Serial dilutions of sCD8
diluted in HBS-EP buffer were flowed over the chip to generate equi-
librium binding data. Data were analyzed using BIAeval, Microsoft
Excel, and Origin version 6.1 (Microcal software). KD values were cal-
culated by non-linear curve fitting assuming 1:1 Langmuir binding (A
B 7 AB) using the equation AB  B  ABmax/(KD  B) and were
verified by linear regression analysis of Scatchard plots.
Tetramerization and Flow Cytometry—Biotinylated pMHCI mono-
mers were conjugated by addition of extravidin-R-phycoerythrin (Sig-
ma) at a pMHCI:extravidin molar ratio of 4:1 to produce tetrameric
pMHCI complexes. Once prepared, tetramers were stored in the dark at
4 °C. 1  105 CD8 CTL in 20 l of phosphate-buffered saline (PBS)
were stained with 1 g of phycoerythrin-tetramer (pMHCI content) for
20 min at 37 °C, washed twice in PBS, and then analyzed using a
FACScalibur flow cytometer (BD Biosciences) with Cell Quest software.
All pMHCI multimers used in this study were made fresh for the week
of use from pMHCI monomers stored at80 °C to avoid the effect of the
stability differences documented in Fig. 3. Where comparisons were
made between the activation induced by different pMHCI multimers
they were tested by FACS to ensure that they exhibited an equal ability
to bind to cell surface TCR.
ELISA for Soluble Lymphokines—Immortalized B cell lines were
washed once in RPMI media and pulsed with peptide for 1 h at 37 °C,
5% CO2. Peptide-pulsed B cell lines and CTL were each washed twice in
RPMI and brought to a concentration of 5  105 cells/ml in RPMI
medium supplemented with 2% fetal calf serum. 5  104 CTL and 5 
104 B cells were incubated together in a 200 l final volume for 4 h or
30 min at 37 °C, 5% CO2 in 96-well U-bottomed plates. Supernatant
was harvested with care not to disturb cells and assayed for MIP-1 and
RANTES by ELISA (R & D Systems). Standard deviation from the
mean of two duplicate assays is shown.
ELISpot Assay for Single-cell IFN- Release—96-Well polyvinylidene
difluoride-backed plates (Millipore) were coated with IFN- capture
antibody 1-DIK (Mabtech) at 15 g/ml, and blocked with RPMI contain-
ing 10% fetal calf serum. 5  104 B cells and 2  102 CTL  peptide
were applied to duplicate wells of pre-coated plates and incubated for
3 h at 37 °C, 5% CO2. Plates were washed 6 times with PBS (Sigma) at
room temperature and incubated for 90 min with 1 g/ml anti-IFN-
mAb-7B6-1 biotin (Mabtech). After 6 further washes, a 1:1000 dilution
of alkaline phosphatase-conjugated streptavidin (Mabtech) was added
and incubated at room temperature for 40 min. After further washing,
chromogenic AP substrate (Bio-Rad) was added for 30 min and devel-
opment was stopped by rinsing twice with water. Spots were counted
mechanically using an ELISpot Reader system ELR02 (Autoimmun
Diagnostika; Strassberg). Standard deviation from the mean of two
duplicate assays is shown.
Stimulation of CTL for Subsequent Immunoblotting—CTL were
washed twice in RPMI and incubated overnight in RPMI with 10% fetal
calf serum. The following day, fetal calf serum was washed off with two
changes of RPMI and 106 CTL were resuspended in 10 l of RPMI. After
10 min at 37 °C in 5% CO2, CTL were stimulated by incubation with 1
g/ml tetramer for 3 min. The reaction was stopped by washing once
with 0.5 ml of ice-cold PBS, and re-suspending the pellet in cold lysis
buffer (140 mM NaCl, 20 mM Tris, pH 8.0, 10 mM sodium fluoride, 2 mM
EDTA, 20% glycerol, 1% IGEPAL, 1 mM Na3VO4, 10 g/ml aprotinin, 10
g/ml leupeptin) at 5  107 cells/ml.
Antiphosphotyrosine Immunoblots—Cells were lysed on ice for 30
min, then the nuclear fraction was pelleted by centrifugation at
16,000  g for 15 min. The remaining lysate was aspirated and added
to an equal volume of SDS loading buffer (350 mM Tris, pH 6.8, 350 mM
SDS, 30% glycerol, 600 mM dithiothreitol, 175 M bromophenol blue).
The sample was boiled for 6 min with agitation and then loaded into a
12% SDS-PAGE protein gel for electrophoresis at 100 V for 16 h. The
gel, filter papers (Bio-Rad), and nitrocellulose (Amersham Biosciences)
of matching size were equilibrated in ice-cold transfer buffer (48 mM
Tris, 39 mM glycine, 20% methanol) for 10 min. Protein was transferred
from the gel by electrophoresis at 25 V for 50 min. The gel was stained
with Coomassie Blue and the membrane stained with Ponceau S to
verify transfer and equal protein loading. Ponceau S was washed off
with distilled water and then wash buffer (PBS, 0.05% Tween). The
membrane was blocked for 1 h with wash buffer containing 1% bovine
serum albumin, washed, and incubated for 4 h with mouse anti-phos-
photyrosine antibody clone 4G10 (Upstate Biotechnology, 1:1000 in
wash buffer, 0.1% bovine serum albumin). The membrane was washed
again with 3 changes of wash buffer for 10 min each, and incubated with
sheep anti-mouse peroxidase-linked secondary antibody (Amersham
Biosciences, 1:2000 in wash buffer, 2.5% milk powder) for 1.5 h. After 3
further washes the blot was developed using chemiluminescent sub-
strate Supersignal Pico (Perbio). All washes and incubations with an-
tibody were performed at 4 °C. At least 48 h after development, blots
were re-probed for total cellular ZAP 70 to control for protein loading.
To re-probe, the membrane was re-hydrated in wash buffer then incu-
bated with rabbit anti-human ZAP 70 primary antibody (Autogen Bio-
clear, 1:1000 in wash buffer, 2.5% milk powder) for 4 h. The blot was
washed 3 times and incubated with peroxidase-linked anti-rabbit sec-
ondary antibody (Autogen Bioclear, 1:1000 in wash buffer, 2.5% milk
2 HLA A2 and HLA A68 are used to define HLA A*0201 and
HLA*6801 throughout this article.
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powder) for 1.5 h, then washed again and developed as above.
Manufacture of C1R-HLA A68-expressing Cells—Human HLA A68
cDNA was obtained by reverse transcription of total RNA extracted
from human peripheral blood mononuclear cells and PCR amplification
of the specific cDNA. The cDNA was cloned as a BamHI-EcoRI frag-
ment in the retroviral vector pLNSX (Clontech) to obtain the vector
A6801-pLNSX. The D227K/T228A mutations were introduced by site-
directed mutagenesis (Stratagene). The plasmids were introduced by
calcium phosphate precipitation into the xenotropic packaging cell line
PG13 (American Type Culture Collection) for the production of recom-
binant retroviral vectors. After 2 weeks of selection in G418 (800 g/ml;
Sigma) supernatant from producing cells was harvested and used for
transduction of C1R (39) target cells. 5  106 cells were transduced
using 5 ml of viral supernatant in the presence of protamine at a
concentration of 8 g/ml (Sigma) for 16 h and subsequently grown in
selective medium containing G418 (400 g/ml) for 2 weeks. Cell surface
expression of HLA A68 and D227K/T228A HLA A68 was quantified by
flow cytometry. 106 retrovirally transduced cells were washed in PBS,
0.1% bovine serum albumin and incubated with 1 g of anti-HLA class
I (W6/32) antibody for 30 min on ice. The cells were washed twice in
PBS, 0.1% bovine serum albumin and incubated with a fluorescein-
conjugated secondary antibody for 30 min on ice. Cells were washed
twice and analyzed by flow cytometry as described above. Correct re-
folding of HLA A68 and D227K/T228A HLA A68 on the surface of C1R
cells was confirmed by CTL assay. Both of these cells were able to
present antigen to HLA A68-restricted CTL when pulsed with very high
levels of peptide antigen (10 mM) and used in ELISpot assays as
described above.
RESULTS
Generation and Validation of pMHCI and 2m Mutations
That Reduce the CD8 Coreceptor Interaction—The CD8 core-
ceptor makes contacts with both the 3 domain, MHC class I
heavy chain and 2m (5). We have described mutations in the
MHC heavy chain/2m complex that reduce the affinity of
the pMHCI/CD8 interaction without affecting the integrity of
the TCR-binding platform (12, 34, 36). The binding of CD8 to
D227K/T228A HLA A2 is below the current limits of detection
by SPR (12). We simulated non-linear curves on our data by
using the equation y  (P1  x)/(P2  x) and are confident we
would be able to detect binding of CD8 to pMHCI with a KD as
low as 10 mM. Consequently we are confident that the D227K/
T228A mutation reduces the binding of CD8 to HLA-A2 by over
50-fold. We have also previously determined that wild type and
D227K/T228 HLA A2 bind to an HLA A2 influenza matrix-
specific TCR (JM22) and HLA A2 HTLV-1 Tax-specific TCR
(A6) equally well (12). Similarly we have confirmed that the
K58E substitution in 2m has no effect on the binding of TCR
(36). The interaction of soluble CD8 (sCD8) with HLA A2
complexed with the HIV-1, p17 Gag-derived peptide SLYNT-
VATL, and 2m containing the K58E substitution was reduced
by more than 15-fold compared with the SLYNTVATL-HLA A2
complex folded with wild type 2m (KD  2 mM) (Fig. 1). We
have reported that HLA A2 complexed with the influenza ma-
trix-derived peptide GILGFVFTL and K58E2m exhibits
greatly reduced binding to sCD8 (36). This result was con-
firmed here to ensure comparability of results (Fig. 1). Curi-
ously, wild type HLA A2 complexed with wild type 2m and
GILGFVFTL peptide bound sCD8 with a lower affinity than
HLA A2 presenting other peptides (data not shown). This re-
sult is in agreement with previous measurements that show
that ILKEPVHGV-HLA A2 (34) has a higher affinity for CD8
(KD  130 M) than HLA A2 folded with GILGFVFTL peptide
(KD  195 M) (36). It is not clear whether this effect is due to
peptide-induced structural changes transmitted to the HLA A2
3 domain or an artifact of protein folding with the GILG-
FVFTL peptide. As with the wild type complexes, GILG-
FVFTL-HLA A2/K58E2m exhibited slightly lower CD8 bind-
ing than SLYNTVATL-HLA A2/K58E2m (Fig. 1).
Mutations in pMHCI and 2m That Reduce the CD8 Core-
ceptor Interaction Do Not Reduce the Binding of Peptide—MHC
class I structures show that the 3 domain mutations utilized
in this study are removed from the 1/2 peptide-binding plat-
form of these molecules and therefore are unlikely to have
direct effects on the binding of peptide (5). The in vitro refolding
efficiency of pMHCI is highly dependent on the ability of pep-
tide to bind (40). We have taken advantage of this and used
such assays as a measure of peptide binding (40). We find that
this technique is more sensitive than traditional ways of meas-
uring peptide binding (41, 42). The efficiency of in vitro refolds
with D227K/T228A and A245V HLA A2 is equal to that of the
wild type molecule (data not shown). The efficiency of in vitro
refolding with K58E2m is actually slightly better than that
with the wild type molecule. This increased efficiency is likely
due to the increased 2m/MHCI heavy chain interactions that
we have described previously (36). We observe similar refolding
efficiency of wild type HLA A68 and the mutated HLA A68
molecules used in this study (data not shown). In addition, we
have made mammalian expression constructs for green fluo-
rescent protein-HLA A2 fusion proteins. Some HLA A2 muta-
tions are observed to affect transport of such proteins to the cell
surface, possibly as a result of reduced peptide binding. D227K/
T228A and A245V HLA A2 are observed to traffic to the cell
FIG. 1. The effect of K58E2m mutation on the affinity of
sCD8 binding to HLA A2 monomers. SLYNTVATL-HLA A2/2m
(positive control), SLYNTVATL-HLA A2/K58E2m, GILGFVFTL-HLA
A2/K58E2m, and SLYNTVATL-D227K/T228A HLA A2/2m (negative
control) biotinylated monomeric complexes were loaded onto separate
flow cells of a streptavidin-coated research grade CM5 chip (BIAcore,
AB) at 1000 response units (RU). sCD8 was injected at increasing
concentrations through all 4 flow cells. For each concentration of
sCD8 (M), the specific binding was calculated as the difference
between the responses at equilibrium in the experimental flow cells
compared with the negative control. KD of the interaction between
sCD8 and SLYNTVATL-HLA A2/2m (positive control) was calcu-
lated by plotting specific binding against the sCD8 concentration for
non-linear curve analysis. Linear Scatchard plot analysis was also
performed (data not shown). SLYNTVATL-HLA-A2/K58E2m and GIL-
GFVFTL-HLA-A2/K58E2m mutants showed very weak interaction
with sCD8 relative to that seen with SLYNTVATL-HLA A2/2m
(positive control). Even at high sCD8 concentration specific binding
with the K58E mutants does not approach equilibrium. Using the
equation y (P1 x)/(P2 x) simulated non-linear curves were plotted
to represent KD values ranging between 2 and 5 mM. Specific binding
measured for both K58E mutants was then plotted against sCD8
concentration and a comparison with the simulated curves was made.
Using this approach it was suggested that the KD of the interaction
between sCD8 and both K58E mutants is 2 mM but 4 mM.
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surface normally by FACS and confocal microscopy (data not
shown). We have also previously determined that the C1R-HLA
A2 cells used in this study express identical levels of cell sur-
face HLA A2 by FACS analysis with HLA A2 conformation-
specific antibody (12). Differences in peptide loading of mutant
MHCI should demonstrate themselves by a difference in cell
surface expression. As such differences in surface expression
are not observed, and all molecules fold as well as the wild type
molecule in vitro, it seems highly likely that our mutant MHCI
molecules bind peptide as well as the wild type molecules.
The pMHCI/CD8 Coreceptor Interaction Can Be Substan-
tially Reduced yet Remains Biologically Significant—We have
shown previously that the A245V substitution in the 3 domain
of HLA A2 reduces the pMHCI/CD8 interaction by 5-fold (34).
We tested whether this reduced binding maintained biological
activity. The earliest biochemical changes known to occur upon
TCR engagement of pMHC antigen involve the activation of
protein-tyrosine kinases associated with the cytoplasmic do-
mains of the TCR/CD3/coreceptor complex (43). These signal-
ing events can be detected within seconds of antigen engage-
ment and peak within the first 10 min of activation before
rapidly declining (44). We have shown that the human CD8
coreceptor effects CTL activation and antigen sensitivity pri-
marily by mediating these phosphorylation events including
the complete phosphorylation of the TCR  chain (12). The B
cell line C1R (39) expressing full-length HLA A2 was capable of
inducing full phosphorylation of the TCR  chain when present-
ing cognate peptide as expected; similar levels of  phosphoryl-
ation were observed with C1R cells expressing A245V substi-
tuted HLA A2 (Fig. 2A). In contrast, HLA A2 with a D227K/
T228A double substitution, which completely abrogates the
pMHCI/CD8 interaction (12), failed to induce detectable
amounts of fully phosphorylated  chain (Fig. 2A). We also
examined the effects of antigen concentration, on the activation
of CTL, by IFN ELISpot (Fig. 2B). Target cells expressing
A245V-substituted HLA A2 were only marginally impaired in
their ability to activate CTL despite a 5-fold reduction in their
ability to interact with CD8 (Fig. 2B). In contrast, there was a
significant reduction in activation by C1R targets expressing
D227K/T228A HLA A2 (Fig. 2B). These data indicate that the
CD8 T cell coreceptor maintains the majority of its biological
activity even at extremely low binding affinities. To confirm
that this result was affinity related, and not a peculiarity of
structural conformation, we tested the biological effects of
other mutations that similarly reduced the pMHCI/CD8
interaction.
Multimerized wild type HLA A2/2m, HLA A2/K58E2m,
and D227K/T228A HLA A2/2m all bound to cell surface TCR
equally well despite differences in the pMHCI/CD8 interaction
(Fig. 3A). This is consistent with previous work showing that
HLA A2 wild type and CD8 null tetramers exhibit comparable
binding to cell surface TCR even at low concentrations (12). We
noticed that if our pMHCI tetramers were kept at 4 °C for
prolonged periods of time, the staining intensity of those man-
ufactured with the D227K/T228A-mutated HLA A2 heavy
chain was less than for those manufactured with the wild type
heavy chain (Fig. 3B). It therefore appears that the biotiny-
lated D227K/T228A mutated molecule is marginally less stable
at 4 °C than wild type molecules.
We have shown that multimeric forms of pMHCI can induce
an early signaling cascade almost identical to that produced by
the cell surface presentation of antigen and that this signaling
cascade results in effector function (12). Here, we examined the
TCR-mediated early signal transduction cascade induced by
different multimeric forms of pMHCI. Multimerized wild type
HLA A2/2m and HLA A2/K58E2m both induced a good in-
tracellular signal including full phosphorylation of the TCR 
chain (Fig. 4A). Multimerized HLA A2 D227K/T228A failed to
induce an early signal (Fig. 4A) despite being equal to wild type
HLA A2 in terms of cross-linking cell surface TCR. A similar
pattern (HLA A2/2m  HLA A2/K58E2m  D227K/T228A
HLA A2/2m) was observed when multimer-induced RANTES,
MIP1, and IFN- production were examined over a range of
multimer concentrations (Fig. 4, B–D). Thus, HLA A2 folded
with peptide and a K58E variant of 2m can retain the vast
majority of CD8-dependent functional activity despite a greater
than 15-fold reduction (Fig. 1) in CD8 binding.
Naturally Weakened pMHCI/CD8 Coreceptor Interactions
Maintain Biological Function—Previous studies have indi-
FIG. 2. CD8 maintains function at low binding affinities. A,
induction of early signal transduction by C1R cells stably transfected
with HLA A2. Lysates were run on SDS-PAGE and immunoblotted with
anti-phosphotyrosine antibody as described under ‘‘Experimental Pro-
cedures.’’ Data was collected by FluorSMax (Bio-Rad). Relative inten-
sities of the 23-kDa fully phosphorylated form and the 21-kDa partially
phosphorylated form of CD3 -chain (67) are shown. CIR transfectants
were pulsed with the HLA A2-restricted HIV gag-derived epitope
SLYNTVATL at a concentration of 1 M for 1 h and then washed 3
times. Peptide-pulsed C1R transfectants were presented to CTL clone
003 (68) for 10 min. Bars 1, resting CTL (no antigen presenting cells);
2, CTL exposed to unpulsed C1R cells expressing wild type HLA-A2; 3,
CTL exposed to D227K/T228A HLA A2-expressing C1R cells pulsed
with 1 M peptide; 4, CTL exposed to A245V HLA A2-expressing C1R
cells pulsed with 1 M peptide; 5, CTL exposed to C1R cells expressing
wild type HLA-A2 pulsed with 1 M peptide. Equal lane loading was
confirmed as described under ‘‘Experimental Procedures.’’ B, IFN-
release by 003 CTL in response to C1R cells expressing wild type HLA
A2, D227K/T228A HLA A2, or A245V HLA A2. C1R transfectants
pulsed with SLYNTVATL were used as targets for the SLYNTVATL-
specific CTL clone 003 in a 4-h ELISpot assay.
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cated that HLA A68 fails to bind CD8 (45) and that the acti-
vation of HLA A68 CTL is completely independent of the
pMHCI/CD8 interaction (46). Molecular modeling based on the
structures of HLA A2, HLA A68, and the HLA A2/CD8 cocrys-
tal predict that the larger valine residue at position 245 in HLA
A68 distorts the 3 loop of the molecule resulting in a less
energetically favorable interaction with CD8 (5). Our results
(above) show that the A245V substitution in the 3 domain of
HLA A2 retains functional significance despite a 5-fold reduc-
tion in CD8 coreceptor binding affinity. We predicted that this
level of interaction would remain functionally significant in
HLA A68-restricted CTL. To test this, we manufactured HLA
A68 and D227K/T228A HLA A68 as described under ‘‘Experi-
mental Procedures.’’ This double substitution knocks out the
CD8 interaction with HLA A2 (12). We examined the binding of
sCD8 to HLA A68 and D227K/T228A HLA A68 and V245A
HLA A68 by SPR. In contrast to a previous report (45), we
found that sCD8 does indeed bind to HLA A6801 (Fig. 5). As
predicted (5), the binding was of lower affinity than that of
other classical MHC class I molecules (KD  980 M). The
D227K/T228A variant of HLA A68 failed to bind sCD8 (Fig. 5).
We then tested the biological relevance of the naturally weak
HLA A68/CD8 interaction when antigen is presented on the
surface of antigen presenting cells. C1R cells expressing HLA
A68 and D227K/T228A HLA A68 were produced as described
under ‘‘Experimental Procedures.’’ These cells were shown to
express similar levels of MHC class I on their surface by stain-
ing with MHC class I specific antibody (Fig. 6A). C1R HLA A68
and C1R HLA D227K/T228A A68 were used to present antigen
to HLA A68-restricted CTL specific for a HIV-1 Tat epitope
(ITKGLGISYGR) (37). D227K/T228A HLA A68-expressing
cells were impaired in their ability to activate a HLA A68-
restricted, HIV-1 ITKGLGISYGR-specific CTL clone (c23) (Fig.
6, B and C). Importantly, multimeric forms of HLA A68 and
D227K/T228A HLA A68 folded with ITKGLGISYGR peptide
bound equally well to the cell surface of a CTL line that recog-
nized this antigen thus ruling out any major difference in the
1/2 TCR-binding platform of these molecules (data not
shown). Thus, HLA A68-restricted T cells do exhibit some de-
pendence on the pMHCI/CD8 interaction.
DISCUSSION
Recognition of antigen by CTL is determined by interaction
of both the TCR and its CD8 coreceptor with pMHC I mole-
cules. Four possible roles for CD8 in T cell activation can be
envisaged (24, 47). First, CD8 performs a role in TCR signal
transduction (12). After CTL engage pMHCI, the earliest in-
tracellular events induce specific phosphorylation of tyrosine
residues in the immunoreceptor tyrosine activation motifs
within the cytoplasmic tails of the TCR-associated TCR/CD3/2
complex. The cytoplasmic tail of the CD8 -chain is associated
with the protein-tyrosine kinase p56lck (8). Active p56lck ini-
tiates TCR signal transduction by phosphorylating the immu-
noreceptor tyrosine activation motifs within the TCR/CD3/2
complex. However, functional T cell activation, including p56lck
activation, can be achieved without involving pMHCI/CD8 con-
tacts, for example, with monoclonal antibodies against compo-
nents of the TCR/CD3/2 complex (48, 49). Furthermore, it
remains unclear whether T cell activation by physiological
levels of pMHCI antigen always requires signaling through the
coreceptor or whether this function is dispensable under cer-
tain conditions (48, 50). Second, the co-receptor may have a role
in assisting cell-cell adhesion, helping to tether the T cell to the
antigen presenting cell (51). Third, CD8 may assist the TCR/
pMHCI interaction by binding cooperatively with the TCR to
the same pMHCI molecule (52). Fourth, CD8 may play a role in
the activation of CTL via direct interaction with the TCR (53,
54), rather than pMHCI. Recent evidence suggests that the
TCR/CD8 interaction may favorably influence the distribution
of the TCR on the CTL surface (24). Cooperative binding of TCR
and CD8 to a single pMHCI molecule has been ruled out by
structural (5) and biophysical (24, 32) observations. However, it
remains unclear whether the dominant effect of the pMHCI/
CD8 interaction in the activation of human CTL is a direct
consequence of the binding energy this interaction affords or
the role of this extracellular interaction in the delivery of sig-
naling molecules to the cytoplasmic side of the TCR/CD3/2
complex.
The study of the pMHCI/CD8 interaction has been con-
founded by a number of differences in the systems and meth-
odologies utilized by different groups. First, we have recently
shown that the human pMHCI/CD8 interaction is 4 times
weaker than the equivalent murine interaction in the absence
of glycosylation (12). There are no reported differences in the
TCR/pMHCI interactions of these two species and it is likely
that any pMHCI/CD8 binding effects will be more prominent in
FIG. 3. D227K/T228A HLA A2 3 domain-mutated multimeric
complexes are unstable compared with wild type molecules.
A, 1  105 003 CTL in 20 l of PBS were stained with 1 g (pMHCI
content) of SLYNTVATL-HLA A2/2m, SLYNTVATL-HLA A2/
K58E2m, or SLYNTVATL-D227K/T228A HLA A2/2m multimeric
complexes. Multimeric complexes had been conjugated immediately
prior to staining by addition of a phycoerythrin (PE)-extravidin conju-
gate (Sigma) to biotinylated monomeric complexes produced as de-
scribed previously at a pMHCI:extravidin molar ratio of 4:1. B, stock
solutions of all 3 tetrameric complexes used in A were stored under
identical conditions (4 °C) for 6 weeks and staining subsequently re-
peated as above.
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the mouse rather than the human systems studied here. Sec-
ond, it has been shown that the affinity of the pMHCI/CD8
varies for different human (34) and murine (55) MHC class I
molecules. Third, recent evidence shows that the glycosylation
of CD8 can also affect the binding to MHCI (30, 31). Conse-
quently, the effects of CD8 are likely to vary depending on the
species, T cell, and particular MHCI molecule being studied.
The picture has been further blurred by the use of anti-CD8
antibodies to study the pMHCI/CD8 interaction. We have re-
cently shown that human anti-CD8 ‘‘blocking’’ antibodies block
T cell activation, and staining with multimeric pMHCI, by
interfering with the TCR/pMHCI interaction and not, as pre-
viously assumed, the pMHCI/CD8 interaction.3 Similar find-
ings have recently been reported in the mouse (56). The use of
anti-CD8 antibodies to examine the role of CD8 in CTL activa-
tion does not allow discrimination between the interaction of
CD8 with pMHCI on the surface of the target cell, interaction
with the TCR on the CTL surface, or other possible roles for
CD8.
Previous studies have examined the roles of the extracellular
binding and cytoplasmic lck recruitment components of the
CD8 molecule in murine hybridomas (57, 58). Comparison of
CD8 T cell hybridomas transfected with CD8 and tailless
CD8	 molecules indicate that both can aid interleukin-2 pro-
duction, although restoration by CD8	 is minimal (about 10%
of the wild type molecule). The use of tailless CD8 molecules
also suffers from the same caveat as the use of anti-CD8 anti-
bodies in that it does not allow discrimination between the
interaction of CD8 with pMHCI on the surface of the target cell,
interaction with the TCR on the CTL surface, or other possible
roles for CD8. As other roles of the external domain of CD8
were not appreciated at the time of these murine hybridoma
studies it was believed that the increases in activation afforded
by tailless CD8 molecules were ‘‘presumably achieved by in-
creasing the avidity of the TCR-antigen interaction through
binding of CD8 to class I molecules’’ (58). Due to the inability of
3 L. Wooldridge, S. L. Hutchinson, E. M. Choi, A. Lissina, E. Jones, F.
Mirza, P. R. Dunbar, D. A. Price, V. Cerundolo, and A. K. Sewell,
manuscript in preparation.
FIG. 4. Activation of HLA A2-restricted CTL with multimeric pMHCI with altered CD8 coreceptor interactions. A, activation of early
TCR signal transduction in response to wild type HLA A2 (filled squares), D227K/T228A HLA A2 (filled triangles), or K58E/2m HLA A2 multimers
(open circles). 003 CTL (106/lane) were stimulated for 3 min, and cell lysates were immunoblotted with anti-phosphotyrosine monoclonal antibody
as described. Lane 1, resting CTL presented with no stimulus; lane 2, CTL stimulated with 1 g/ml SLYNTVATL-HLA A2/K58E2m multimer for
3 min; lane 3, CTL stimulated with 1 g/ml SLYNTVATL-D227K/T228A HLA A2/2m multimer for 3 min; lane 4, CTL stimulated with 1 g/ml
SLYNTVATL-wild type HLA A2/2m multimer for 3 min. B–D, soluble lymphokine release by 003 CTL in response to wild type HLA A2/2m,
D227K/T228A HLA A2/2m, or HLA A2/K58E2m multimers, all bearing the SLYNTVATL peptide. Lymphokine release was determined by ELISA
4 h after addition of stimulus as previously described (69). Graphs show the mean  S.D. of two replicate assays. Staining levels determined by
flow cytometric quantification were equivalent with all 3 multimers. Plots are for RANTES (B), MIP1 (C), and IFN- (D) levels in the same
supernatant. Lymphokine released in response to the wild type HLA A2/2m and HLA A2/K58E2m multimers differed most at the lowest antigen
concentrations. These differences are indicated on the plots along with the difference in the pMHCI/CD8 binding of these two multimers.
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anti-CD8 antibodies or the use of tailless CD8 molecules to
distinguish between different roles of the extracellular domain
of CD8 we believe the most desirable way to examine the role of
the pMHCI/CD8 interaction in isolation is to utilize mutations
in pMHCI that affect the pMHCI/CD8 interaction without al-
tering the TCR/pMHCI interaction (12, 36). In this study we
have used mutations in the 3 domain of the MHCI heavy
chain and the 2m subunit that reduce the pMHCI/CD8 inter-
action to probe the significance of pMHC/coreceptor affinity in
the activation of human CTL.
We find that the CD8 coreceptor exhibits disproportionate
biological activity at extremely low binding affinities using
several different systems. First we demonstrated that HLA A2
retains the vast majority of its CD8-dependent functional ac-
tivity when residue 245 is mutated to valine (Fig. 2). This
mutation, which occurs naturally in HLA A68, reduces the
binding of CD8 to HLA A2 by 5-fold (34). We then utilized the
K58E mutation in 2m. This mutation has a more profound
effect on the binding of sCD8. The 15-fold reduction in CD8
binding caused by the K58E mutation in 2m translated into,
at most, a 5.3-, 1.8-, and 2.8-fold reduction in RANTES, MIP1,
and IFN production, respectively (Fig. 4, B–D). Our results
show that CD8 maintains the vast majority of its activity even
when the pMHCI/CD8 interaction is extremely weak (Fig. 2
and 4). Consequently, we favor a model where the dominant
effect of CD8 in the activation of human CTL is not a direct
consequence of the binding energy provided by the extracellu-
lar interaction between pMHCI and CD8. Finally, we examined
the role of CD8 in the activation of HLA A68-restricted T cells
by introducing the D227K/T228A mutation into the 3 domain
of this MHC class I molecule. This double substitution in the 3
domain of MHC class I does not affect the binding of TCRs to
the 1/2 peptide-binding platform of the HLA A2 molecule
(12); there is no reason to assume that this would not be the
case with HLA A68. We studied the structure of the human
class I histocompatibility antigen Aw68.1 solved at 1.9-Å reso-
lution and deposited in the Protein Data Bank (59) as 1hsb (60).
The distances between the C atoms of residues Asp-227, Thr-
228, and Val-245 and the centroid of the presented peptide
were 46.3 Å, 43.2 Å, and 39.6 Å, respectively. These extremely
large distances support the hypothesis that mutating Asp-227,
Thr-228, and Ala-245 residues would be unlikely to affect the
1/2 peptide-presenting platform. Furthermore, multimeric
FIG. 5. The affinity of sCD8 binding to HLA-A68/2m mono-
mers. ITKGLGISYGR-HLA A68 (squares), ITKGLGISYGR-D227K/
T228A HLA A68 (triangles), and ITKGLGISYGR-V245A HLA A68 (cir-
cles) were loaded onto separate flow cells of a streptavidin-coated
research grade CM5 chip (BIAcore AB) at 1000 response units (RU).
A third flow cell was loaded with biotinylated sTCR, specific for the
HLA A2-restricted HLTV-1 Tax epitope LLFGYPVYV at 1000 RU, to
act as a negative control. sCD8 was injected at increasing concentra-
tions through all 4 flow cells. For each concentration of sCD8 (M) the
specific binding was calculated as the difference between the responses
at equilibrium in the experimental flow cells compared with the nega-
tive control. Specific binding was then plotted against the sCD8
concentration for non-linear curve analysis. Linear Scatchard plot anal-
ysis was also performed (data not shown).
FIG. 6. HLA A68-restricted CTL exhibit dependence on the
pMHCI/CD8 interaction. A, expression of HLA A68 and D227K/
T227A HLA A68 on the surface of retrovirally transduced C1R cells
quantified by flow cytometry. 106 cells were prepared and stained with
1 g of anti-HLA class I (W6/32) antibody for 30 min on ice as described
under ‘‘Experimental Procedures.’’ The data are representative of three
separate experiments. B, CD8-dependent release of MIP-1 by c23 CTL
stimulated with ITKGLGISYGR-presenting C1R cells expressing wild
type HLA A68 (squares) or D227K/T228A HLA A68 (triangles). MIP-1
release was determined at 4 h by ELISA. C, release of IFN- by c23 CTL
stimulated with ITKGLGISYGR-pulsed C1R cells expressing wild type
HLA A68 (squares) or D227K/T228A HLA A68 (triangles). IFN- re-
lease was determined at 4 h by ELISpot.
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forms of HLA A68 and D227K/T228A HLA A68 folded with the
ITKGLGISYGR peptide bound to CTL at equivalent levels
(data not shown), thus, providing experimental support for this
prediction. Previous studies have reported that HLA A68 does
not bind to CD8 and that A68-restricted CTL are completely
independent of the pMHCI/CD8 interaction (45, 46). In keeping
with the results above, however, we found that: (i) the natural
mutation that occurs in the 3 domain (A245V) of HLA A68
does bind CD8, albeit with a markedly reduced affinity (KD 
980 M; Fig. 5), and (ii) this HLA A68/CD8 interaction is
functionally significant in the natural setting (Fig. 6). Indeed,
the very existence of HLA A68-restricted CTL is evidence, in
itself, of a functional HLA A68/CD8 interaction. CD8-deficient
mice fail to develop CTL suggesting a role for the pMHCI/CD8
interaction in thymic selection (61). This has been confirmed
using transgenic MHCI molecules impaired in their inter-
action with CD8 (62–65). Whereas there are differences in the
pMHCI/CD8 interaction between mouse and human (66), it is
reasonable to assume that this interaction is also important for
the development of human CTL. There is no evidence that HLA
A68-positive individuals are impaired in the development of
A68-restricted CTL. Thus, the reduced affinity of this molecule
for CD8 appears sufficient for T cell development in addition to
having functional significance in the periphery.
It should be noted that the energy of the pMHCI/CD8 inter-
action still plays a role in the activation of human antiviral
CTL. Changes in the dose-response curve generated by antigen
with extremely weak pMHCI/CD8 interactions show that the
binding energy of this interaction has significant effects, par-
ticularly at very low antigen concentrations (Figs. 2B and 4,
B–D). Whereas these decreases in CTL sensitivity are not in
proportion to the decreases in pMHCI/CD8 binding, they dem-
onstrate that the binding energy of this interaction plays a role
in enhancing the sensitivity of human anti-viral CTL. The
increase in sensitivity afforded by this binding energy may be
particularly relevant in vivo where antigen is likely to be
limiting.
The affinities of the pMHCI/CD8 and pMHCII/CD4 interac-
tions are extremely low (KD  100 M) (32–34). Cell-cell adhe-
sion molecules that interact with 1:1 stoichiometry typically do
so with higher affinity (7, 32). The extraordinarily low affinity
of the pMHC/coreceptor interaction is unlikely to be the result
of an evolutionary accident. We suggest that the uniquely low
affinity of the pMHC/coreceptor interaction is critical for T cell
specificity. The binding sites for CD8 and CD4 are separate
from the TCR-recognized (2), peptide-binding domains of MHC
molecules, and allow a single MHC molecule to be bound si-
multaneously by both TCR and CD8 or CD4 (5, 6). The highly
variable complementarity determining regions of the TCR,
which interact with the peptide-binding platform of pMHCI,
confer antigen specificity to the T cell recognition process (1, 2).
We have measured the human TCR/pMHCI interaction for 12
TCR/ligand pairs4 and observe a median KD of 10 M. We
have also measured equilibrium binding of pMHCI and CD8 for
a variety of different HLA gene products and find that it has a
KD in excess of 100 M (34). Thus, the human TCR/pMHCI
interaction is generally 10-fold higher than the pMHCI/CD8
interaction. As it is the highly variable TCR that determines
the specificity of pMHC recognition, it is essential that the
affinity of the TCR/pMHC interaction dominates the interac-
tion of pMHC with the invariant coreceptor in TCR/pMHCI/
CD8 or TCR/pMHCII/CD4 interactions. We predict that an
increased interaction between the pMHC and coreceptor would
compromise T cell specificity. Experiments to test this hypoth-
esis are currently in progress.
In summary, we have shown that the pMHCI/CD8 interac-
tion can maintain substantial biological activity at extremely
low binding affinities. Whereas our findings show that the
binding energy of the pMHCI/CD8 interaction has some biolog-
ical significance it does not represent the dominant role of the
CD8 coreceptor in the activation of natural anti-viral human
CTL. The binding energy provided by the pMHCI/CD8 inter-
action may play a more significant role in the activation of
murine CTL, or human CTL with weak TCR/pMHCI interac-
tions. However, the dominant role for the extracellular pMHCI/
CD8 interaction in the activation of the human anti-viral CTL
studied here appears to be the delivery of signaling molecules
to the cytoplasmic side of the TCR/CD3/2 complex.
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